Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) is set to release its earnings data before the market opens on Wednesday, November 6th. Analysts expect Arbutus Biopharma to post earnings of ($0.09) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Arbutus Biopharma had a negative return on equity of 66.68% and a negative net margin of 766.20%. The company had revenue of $1.73 million during the quarter, compared to analyst estimates of $1.54 million. During the same quarter in the previous year, the business posted ($0.10) earnings per share. On average, analysts expect Arbutus Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Arbutus Biopharma Stock Performance
Shares of NASDAQ ABUS traded down $0.10 during trading on Wednesday, hitting $3.94. 434,884 shares of the company traded hands, compared to its average volume of 1,119,725. The business's fifty day moving average is $4.03 and its 200 day moving average is $3.53. The firm has a market capitalization of $743.54 million, a price-to-earnings ratio of -9.18 and a beta of 1.91. Arbutus Biopharma has a fifty-two week low of $1.70 and a fifty-two week high of $4.72.
Analyst Ratings Changes
A number of equities analysts have issued reports on ABUS shares. JMP Securities lifted their price target on Arbutus Biopharma from $4.00 to $5.00 and gave the company a "market outperform" rating in a research note on Friday, August 2nd. Jefferies Financial Group upped their price target on Arbutus Biopharma from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Thursday, September 5th. Finally, StockNews.com upgraded Arbutus Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, August 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $5.25.
Check Out Our Latest Stock Report on ABUS
Arbutus Biopharma Company Profile
(
Get Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
See Also
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
